

Factsheet FY/2015



COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 220,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	FY/2015	Change	FY/2014	Change
Sales and Earnings				
Sales	27,626	19%	23,231	14%
EBIT ¹	3,958	25%	3,158	4%
Net income (before special items) ²	1,423	31%	1,086	3%
Earnings per ord. share in € (before special items) ²	2.61	30%	2.01	3%
Balance sheet and cash flow				
Total assets ⁴	43,170	9%	39,788	22%
Non-current assets ⁴	32,253	8%	29,776	21%
Equity ³	18,003	16%	15,483	17%
Equity ratio ^{3,4}	42%	--	39%	--
Net debt/EBITDA ^{4,5,6}	2.68	--	3.24	--
Investments ⁷	2,029	-47%	3,795	-1%
Operating cash flow	3,327	29%	2,585	11%
Operating cash flow in % of sales	12.0%	--	11.1%	--
Profitability				
EBIT margin ¹	14.3%	--	13.6%	--
Return on equity after taxes (ROE) ^{1,2}	13.0%	--	11.6%	--
Return on operating assets (ROOA) ^{4,5}	10.1%	--	9.1%	--
Return on invested capital (ROIC) ^{4,5}	8.3%	--	7.5%	--
Employees (December, 31)	222,305	3%	216,275	21%

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

³ Including noncontrolling interest

⁴ 2014 adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU 2015-03)


⁵ 2014 - 2015 before special items; 2014 pro forma acquisitions;

⁶ At LTM average exchange rates for both net debt and EBITDA

⁷ Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of December 31, 2015


BUSINESS SEGMENTS

€ in millions		FY/2015	Change	FY/2014	Change
FRESENIUS MEDICAL CARE	Sales	15,086	27%	11,917	8%
	EBIT	2,097	24%	1,697	0%
FRESENIUS KABI	Sales	5,950	16%	5,146	3%
	EBIT ¹	1,189	36%	873	-6%
FRESENIUS HELIOS	Sales	5,578	6%	5,244	55%
	EBIT ¹	640	16%	553	42%
FRESENIUS VAMED	Sales	1,118	7%	1,042	2%
	EBIT	64	8%	59	7%


¹ Before special items

- ▶ **Fresenius Medical Care** is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. As of December 31, 2015, Fresenius Medical Care was treating 294,381 patients in 3,418 dialysis clinics.
- ▶ **Fresenius Kabi** Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
- ▶ **Fresenius Helios** is Germany's largest hospital operator. HELIOS operates 111 hospitals, thereof 87 acute care clinics (including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal) and 24 post-acute care clinics. HELIOS treats more than 4.7 million patients per year, thereof more than 1.3 million inpatients, and operates more than 34,000 beds.
- ▶ **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

SALES BY REGION




SALES BY BUSINESS SEGMENT



FRESENIUS SHARE/ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (Dezember 31, 2015)	545,727,950
Market capitalization (Dezember 31, 2015)	€36.0 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT SHARE DIVIDENDS IN €¹



This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Maturity
Fresenius Finance B. V.	XS1013954646	€300	2.375%	2019
Fresenius Finance B. V.	XS0759200321	€500	4.25%	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875%	2020
Fresenius Finance B. V.	XS1013955379	€450	3.00%	2021
Fresenius Finance B. V.	XS1026109204	€450	4.00%	2024
Fresenius US Finance II, Inc.	USU31436AG04	US\$300	4.25%	2021
Fresenius US Finance II, Inc.	USU31436AH86	US\$300	4.50%	2023
Convertible bonds				
Fresenius SE & Co. KGaA	DE000A1YC3T6	€500	0.00%	2019

Bonds of Fresenius Medical Care can be found under www.freseniusmedicalcare.com/en/home/investors/credit-relations

SHARE PERFORMANCE¹

1 month	-5,1%
3rd quarter	+9,9%
1 year	+52,8%
5 years	+215,3%
10 years	+460,5%

¹ Effective date/closing price: December 31, 2015

GROUP OUTLOOK 2016

	Targets 2016
Sales, growth (in constant currency)	6% – 8%
Net income ¹ , growth (in constant currency)	8% – 12%
Capital expenditure	~6% of group sales

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs (€12 million before tax for hospitals acquired from Rhön-Klinikum AG), before costs for the efficiency program at Fresenius Kabi (€105 million before tax) and before disposal gains from the divestment of two HELIOS hospitals (€34 million before tax)

For the outlook of the business segments please see the Investor News of February 24, 2016.

FINANCIAL CALENDAR

	Dates
Report on 1st quarter 2016	May 3, 2016
Annual General Meeting, Frankfurt/Main	May 13, 2016
Report on 2nd quarter 2016	August 2, 2016
Report on 3rd quarter 2016	October 27, 2016

Please note that these dates could be subject to modifications.

CONTACT

Fresenius SE & Co. KGaA

Eise-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi

Senior Vice President Telephone: ++49 61 72 6 08-24 85
Investor Relations Telefax: ++49 61 72 6 08-24 88

Follow us on twitter

[@Fresenius_IR folgen](https://twitter.com/Fresenius_IR)